公司資料
TG Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TGTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
49.28 USD (+1.11%)
收盤價
最後更新: 2026年8月17日
5.61B USD
市值
股價為何變動
As of Aug 17, 2026, TGTX closed up 1.11% at $49.28. No new same-company headline was identified in the current news window.
公司概覽
B-Cell-Directed Therapies
TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program.
BRIUMVI
BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. The antibody is designed for efficient B-cell depletion at a relatively low dose and is commercialized in the United States and through partners internationally.
Formulation and Dosing Expansion
The company is conducting a pivotal program for subcutaneous ublituximab and the ENHANCE trial of a consolidated intravenous Day 1 and Day 15 dosing regimen. These studies aim to make administration more convenient while maintaining the established mechanism.
Azer-Cel in Progressive MS
Azer-cel is an allogeneic CAR-T therapy being evaluated in progressive multiple sclerosis and other autoimmune diseases. The program tests whether deeper immune-cell resetting can benefit patients beyond conventional antibody-mediated B-cell depletion.
未來催化劑
- Topline ENHANCE pivotal data for consolidated intravenous BRIUMVI dosing expected in mid-2026.
- Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
- Pivotal subcutaneous BRIUMVI topline data expected around year-end 2026 or the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。